 Fibromyalgia is a syndrome characterized by widespread musculoskeletal pain and hyperalgesia with a prevalence of 2-4 in the general population; it is often accompanied by fatigue, insomnia, anxiety, depression and other conditions. It is a difficult condition to treat, and only recently have drugs been approved by the FDA specifically for the treatment of this condition Lyrica was approved in 2007, Duloxetine in 2008. There are now several clinical trials of drugs commonly used to treat neuropathic pain amitriptyline, gabapentin, pregabalin, acetaminophentramadol, duloxetine, minserin reporting some degree of efficacy in treating fibromyalgia. This efficacy makes it practical to consider fibromyalgia along with other neuropathic pain conditions. However, such drug trials report only partial efficacy in relieving pain andor other symptoms. Current treatment recommendations indicate the need for a multimodal approach; this includes medical management using appropriate drug therapies, psychological therapies, exercise and complementary approaches. The current proposal is for a randomized controlled trial to compare qigong a complementary modality to a wait list control to determine if qigong is a useful complementary therapy for fibromyalgia. 